Relevant bibliographies by topics / Anti-infective agents / Journal articles

Journal articles on the topic 'Anti-infective agents'

To see the other types of publications on this topic, follow the link: Anti-infective agents.
Author: Grafiati
Published: 4 June 2021
Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Anti-infective agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tomioka, Haruaki. "Anti-infective Agents." Current Pharmaceutical Design 27, no. 38 (October 25, 2021): 3947–48. http://dx.doi.org/10.2174/138161282738211011151923.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zopf, D., and S. Roth. "Oligosaccharide anti-infective agents." Lancet 347, no. 9007 (April 1996): 1017–21. http://dx.doi.org/10.1016/s0140-6736(96)90150-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kidwai, M., S. Saxena, S. Rastogi, and R. Venkataramanan. "Pyrimidines as Anti-Infective Agents." Current Medicinal Chemistry -Anti-Infective Agents 2, no. 4 (December 1, 2003): 269–86. http://dx.doi.org/10.2174/1568012033483015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sbaraglini, María, and Alan Talevi. "Hybrid Compounds as Anti-infective Agents." Current Topics in Medicinal Chemistry 17, no. 9 (February 13, 2017): 1080–95. http://dx.doi.org/10.2174/1568026616666160927160912.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sardari, S., and M. Dezfulian. "Cheminformatics in Anti-Infective Agents Discovery." Mini-Reviews in Medicinal Chemistry 7, no. 2 (February 1, 2007): 181–89. http://dx.doi.org/10.2174/138955707779802633.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kirst, Herbert A. "Circumventing resistance to anti-infective agents." Expert Opinion on Pharmacotherapy 16, no. 2 (January 5, 2015): 149–50. http://dx.doi.org/10.1517/14656566.2015.1002669.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tschida, Suzanne J., Kyle Vance-Bryan, and Darwin E. Zaske. "Anti-infective agents and hepatic disease." Medical Clinics of North America 79, no. 4 (1995): 895–917. http://dx.doi.org/10.1016/s0025-7125(16)30045-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lakshmaiah Narayana, Jayaram, and Jyh-Yih Chen. "Antimicrobial peptides: Possible anti-infective agents." Peptides 72 (October 2015): 88–94. http://dx.doi.org/10.1016/j.peptides.2015.05.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ludwig, Beatrice S., João D. G. Correia, and Fritz E. Kühn. "Ferrocene derivatives as anti-infective agents." Coordination Chemistry Reviews 396 (October 2019): 22–48. http://dx.doi.org/10.1016/j.ccr.2019.06.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Spina, Edoardo, Maria Antonietta Barbieri, Giuseppe Cicala, and Jose de Leon. "Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents." Pharmaceuticals 13, no. 12 (December 2, 2020): 439. http://dx.doi.org/10.3390/ph13120439.

Full text
Abstract:
This is a comprehensive review of the literature on drug interactions (DIs) between atypical antipsychotics and anti-infective agents that focuses on those DIs with the potential to be clinically relevant and classifies them as pharmacokinetic (PK) or pharmacodynamic (PD) DIs. PubMed searches were conducted for each of the atypical antipsychotics and most commonly used anti-infective agents (13 atypical antipsychotics by 61 anti-infective agents/classes leading to 793 individual searches). Additional relevant articles were obtained from citations and from prior review articles written by the authors. Based on prior DI articles and our current understanding of PK and PD mechanism, we developed tables with practical recommendations for clinicians for: antibiotic DIs, antitubercular DIs, antifungal DIs, antiviral DIs, and other anti-infective DIs. Another table reflects that in clinical practice, DIs between atypical antipsychotics and anti-infective agents occur in patients also suffering an infection that may also influence the PK and PD mechanisms of both drugs (the atypical antipsychotic and the anti-infective agent(s)). These tables reflect the currently available literature and our current knowledge of the field and will need to be updated as new DI information becomes available.
APA, Harvard, Vancouver, ISO, and other styles
11

Lee, Ngan, and John Ho. "Celastrol and Terpenes as Anti-Infective Agents." Anti-Infective Agents in Medicinal Chemistry 7, no. 2 (April 1, 2008): 97–100. http://dx.doi.org/10.2174/187152108783954632.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Ho, John. "Bioactive Herbal Alkaloids as Anti-Infective Agents." Anti-Infective Agents 11, no. 1 (November 1, 2012): 70–74. http://dx.doi.org/10.2174/22113626130108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Schuck, Edgar L., and Hartmut Derendorf. "Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents." Expert Review of Anti-infective Therapy 3, no. 3 (June 2005): 361–73. http://dx.doi.org/10.1586/14787210.3.3.361.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Sharma, Prabodh, Kushal Bansal, Aakash Deep, and Meenakshi Pathak. "Benzothiazole Derivatives as Potential Anti-Infective Agents." Current Topics in Medicinal Chemistry 17, no. 2 (November 20, 2016): 208–37. http://dx.doi.org/10.2174/1568026616666160530152546.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Barrett, Michael P., Curtis G. Gemmell, and Colin J. Suckling. "Minor groove binders as anti-infective agents." Pharmacology & Therapeutics 139, no. 1 (July 2013): 12–23. http://dx.doi.org/10.1016/j.pharmthera.2013.03.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Michalopoulos, A., and E. Papadakis. "Inhaled Anti-infective Agents: Emphasis on Colistin." Infection 38, no. 2 (February 27, 2010): 81–88. http://dx.doi.org/10.1007/s15010-009-9148-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Adermann, Knut. "Defensins as anti-infective and immunomodulatory agents." Expert Opinion on Therapeutic Patents 16, no. 9 (August 31, 2006): 1223–34. http://dx.doi.org/10.1517/13543776.16.9.1223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Casadevall, Arturo. "Antibody-based therapies as anti-infective agents." Expert Opinion on Investigational Drugs 7, no. 3 (March 1998): 307–21. http://dx.doi.org/10.1517/13543784.7.3.307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Venugopalan, Veena, and Craig A. Martin. "Selecting Anti-infective Agents for the Treatment of Bone Infections: New Anti-infective Agents and Chronic Suppressive Therapy." Orthopedics 30, no. 10 (October 1, 2007): 832–34. http://dx.doi.org/10.3928/01477447-20071001-16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Jagtap Sachin Pishwikar, Sagar. "Design Synthesis and Screening of Mannich Bases of Alliin as Anti - Infective Agents." International Journal of Science and Research (IJSR) 12, no. 6 (June 5, 2023): 989–92. http://dx.doi.org/10.21275/sr23606132539.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Carmona-Ribeiro, Ana, Debora Vieira, and Nilton Lincopan. "Cationic Surfactants and Lipids as Anti-Infective Agents." Anti-Infective Agents in Medicinal Chemistry 5, no. 1 (January 1, 2006): 33–51. http://dx.doi.org/10.2174/187152106774755572.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

de Oliveira, Jarbas, Fernanda Nunes, Melissa Simoes Pires, Denizar Alberto Silva Melo, and Marcio Fagundes Donadio. "Antibodies as Anti-Infective Agents in Medicinal Chemistry." Anti-Infective Agents in Medicinal Chemistry 7, no. 4 (October 1, 2008): 249–57. http://dx.doi.org/10.2174/187152108785908811.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Butler,, Dawn R., Robert J. Kuhn, and Mary H. H. Chandler. "Pharmacokinetics of Anti-Infective Agents in Paediatric Patients." Clinical Pharmacokinetics 26, no. 5 (May 1994): 374–95. http://dx.doi.org/10.2165/00003088-199426050-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Nugraha, Ari S., and Paul A. Keller. "Revealing Indigenous Indonesian Traditional Medicine: Anti-infective Agents." Natural Product Communications 6, no. 12 (December 2011): 1934578X1100601. http://dx.doi.org/10.1177/1934578x1100601240.

Full text
Abstract:
Indonesia is rich in medicinal plants which the population has used traditionally from generation to generation for curing diseases. Our interest in the treatment of infectious diseases has lead to the investigation of traditional Indonesian treatments. In this review, we present a comprehensive review of ethnopharmacologically directed screening in Indonesian medicinal plants to search for new antiviral, antimalarial, antibacterial and antifungal agents. Some potent drug leads have been isolated from Indonesian medicinal plants. Further research is still required for the lead development as well as the search for new bioactive compounds from the enormous medicinal plant resources.
APA, Harvard, Vancouver, ISO, and other styles
25

D’Avolio, Antonio, Debora Pensi, Lorena Baietto, and Giovanni Di Perri. "Therapeutic drug monitoring of intracellular anti-infective agents." Journal of Pharmaceutical and Biomedical Analysis 101 (December 2014): 183–93. http://dx.doi.org/10.1016/j.jpba.2014.03.040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Guirao, Xavier. "Empiric anti-infective agents of intra-abdominal infection." Cirugía Española (English Edition) 87, no. 2 (January 2010): 61–62. http://dx.doi.org/10.1016/s2173-5077(10)70164-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Edwards, Paul. "Pyrimidin-4-yl phenols as anti-infective agents." Drug Discovery Today 11, no. 15-16 (August 2006): 768–69. http://dx.doi.org/10.1016/j.drudis.2006.06.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Atillasoy, Cem, and Panagiotis Gourlias. "1235. On the Edge of Tomorrow: Expedited Regulatory Pathways for Anti-Infective Therapies." Open Forum Infectious Diseases 7, Supplement_1 (October 1, 2020): S637. http://dx.doi.org/10.1093/ofid/ofaa439.1420.

Full text
Abstract:
Abstract Background The FDA has developed expedited review programs and pathways to increase drug development for products that have a major clinical benefit. These programs include: Fast Track, Orphan Drug Status, Accelerated Approval, Priority Review, Breakthrough Therapy (BTD) and Qualified Infectious Disease Products (QIPD). Given the heightened awareness of infectious diseases--and emerging global threats, such as resistant bacteria and Ebola—academia and industry have developed and received approval for 88 new infectious disease agents. The objective of this study was to assess the use of expedited review pathways for the 88 anti-infective agents that were approved between 2001-2020. FDA Expedited Drug Development Programs Methods We analyzed the FDA Drug Approval Database entitled, “Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals” for anti-infective therapies that were approved after 2000. Anti-infective therapies were defined as agents that were used to treat or prevent infectious diseases and include antibiotics, antivirals and antifungals. Our analysis focused on a comparison of the percentage of approved anti-infective agents that used each of the aforementioned designations across 2 decades (2001-2010 & 2011-2020). A drug may have one, none, or multiple of these designations. Results There were significant differences in the percentage of anti-infective agents approved with priority review, fast track and accelerated approval in 2001-2010 compared to 2011-2020 (See Results Figure 1) BTD and QIDP did not exist until 2012, thus preventing comparisons between decades. QIDP • Between 2012-2020, 16 anti-infectives have been approved with QIDP. From 2017-2020, 40% (n=10) of approved anti-infectives had QIDP. Orphan Drug Status: • Between 2017-2020, 32% of anti-infectives approved have the orphan drug designation. Comparison of FDA Expedited Drug Development Programs use between 2001-2010 and 2011-2020 Conclusion Our findings indicate Priority Review and Fast Track use has increased since 2010 among anti-infective products. Additionally, our analyses indicate that since 2017 there has been increased use of Orphan Drug Status and QIDP. However, there has been limited use of Breakthrough Therapy and Accelerated Approvals. These two pathways should be increasingly considered by academia, industry and the FDA to further expedite innovative anti-infective development. Disclosures All Authors: No reported disclosures
APA, Harvard, Vancouver, ISO, and other styles
29

Kowalski, Regis P., Shannon V. Nayyar, Eric G. Romanowski, and Vishal Jhanji. "Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections." Antibiotics 11, no. 2 (February 6, 2022): 204. http://dx.doi.org/10.3390/antibiotics11020204.

Full text
Abstract:
The treatment of eye infections is very different than treating other body infections that require systemic anti-infectives. Endophthalmitis, keratitis, conjunctivitis, and other ocular infections are treated with direct injection and with topical drops directly to the infection site. There are no anti-infective susceptibility standards to interpret treatment success, but the systemic standards can be used to guide ocular therapy if the concentration of anti-infective in the ocular tissue is assumed to be higher than the concentration in the blood serum. This Perspective describes: (1) eye infections, (2) diagnostics of eye infections, (3) anti-infective treatment of eye infections, (4) anti-infective resistance of ocular pathogens, and (5) alternative anti-infective delivery and therapy. The data, based on years of clinical and laboratory research, support the premise that ocular infections are less problematic if etiologic agents are laboratory-diagnosed and if prompt, potent, anti-infective therapy is applied. Anti-infective susceptibility should be monitored to assure continued therapeutic success and the possibility of new-found resistance. New delivery systems and therapies may be helpful to better treat future ocular infections.
APA, Harvard, Vancouver, ISO, and other styles
30

Gray-Davis, Yolanda N., and Anne Mounsey. "Are oral anti-infective agents effective for pityriasis rosea?" Evidence-Based Practice 17, no. 5 (May 2014): E12. http://dx.doi.org/10.1097/01.ebp.0000540661.00859.7d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Hanes, Philip J., and James P. Purvis. "Local Anti-Infective Therapy: Pharmacological Agents. A Systematic Review." Annals of Periodontology 8, no. 1 (December 2003): 79–98. http://dx.doi.org/10.1902/annals.2003.8.1.79.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Koirala, Niranjan. "Medicinal/Pharmaceutical Chemistry and Engineering of Anti-infective Agents." Anti-Infective Agents 19, no. 5 (December 7, 2021): 2. http://dx.doi.org/10.2174/221135251905211206161418.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Lagardère, Prisca, Cyril Fersing, Nicolas Masurier, and Vincent Lisowski. "Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents." Pharmaceuticals 15, no. 1 (December 27, 2021): 35. http://dx.doi.org/10.3390/ph15010035.

Full text
Abstract:
Thienopyrimidines are widely represented in the literature, mainly due to their structural relationship with purine base such as adenine and guanine. This current review presents three isomers—thieno[2,3-d]pyrimidines, thieno[3,2-d]pyrimidines and thieno[3,4-d]pyrimidines—and their anti-infective properties. Broad-spectrum thienopyrimidines with biological properties such as antibacterial, antifungal, antiparasitic and antiviral inspired us to analyze and compile their structure–activity relationship (SAR) and classify their synthetic pathways. This review explains the main access route to synthesize thienopyrimidines from thiophene derivatives or from pyrimidine analogs. In addition, SAR study and promising anti-infective activity of these scaffolds are summarized in figures and explanatory diagrams. Ligand–receptor interactions were modeled when the biological target was identified and the crystal structure was solved.
APA, Harvard, Vancouver, ISO, and other styles
34

Rodvold, Keith A., Liz Yoo, and Jomy M. George. "Penetration of Anti-Infective Agents into PulmonaryEpithelial Lining Fluid." Clinical Pharmacokinetics 50, no. 11 (November 2011): 689–704. http://dx.doi.org/10.2165/11592900-000000000-00000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Pennington, J. E. "Newer uses of intravenous immunoglobulins as anti-infective agents." Antimicrobial Agents and Chemotherapy 34, no. 8 (August 1, 1990): 1463–66. http://dx.doi.org/10.1128/aac.34.8.1463.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Vazquez, Jose A., and Jack D. Sobel. "Reviews Of Anti‐infective Agents: Anidulafungin: A Novel Echinocandin." Clinical Infectious Diseases 43, no. 2 (July 15, 2006): 215–22. http://dx.doi.org/10.1086/505204.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Ritz, Nicole, Julia Bielicki, Marc Pfister, and John van den Anker. "Therapeutic Drug Monitoring for Anti-infective Agents in Pediatrics." Pediatric Infectious Disease Journal 35, no. 5 (May 2016): 570–72. http://dx.doi.org/10.1097/inf.0000000000001091.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Sivakumar, P. M., S. Prabhu Seenivasan, Vanaja Kumar, and Mukesh Doble. "Novel 1,3,5-triphenyl-2-pyrazolines as anti-infective agents." Bioorganic & Medicinal Chemistry Letters 20, no. 10 (May 2010): 3169–72. http://dx.doi.org/10.1016/j.bmcl.2010.03.083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Rubin, Harvey, Trevor Selwood, Takahiro Yano, Damian G. Weaver, H. Marie Loughran, Michael J. Costanzo, Richard W. Scott, Jay E. Wrobel, Katie B. Freeman, and Allen B. Reitz. "Acinetobacter baumannii OxPhos inhibitors as selective anti-infective agents." Bioorganic & Medicinal Chemistry Letters 25, no. 2 (January 2015): 378–83. http://dx.doi.org/10.1016/j.bmcl.2014.11.020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Li, Kuang-pang. "Analysis for drugs and metabolites including anti-infective agents." Microchemical Journal 43, no. 1 (February 1991): 86. http://dx.doi.org/10.1016/0026-265x(91)90043-o.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

YAGISAWA, MORIMASA, and KEISUKE SUNAKAWA. "Trends in development of anti-infective agents in Japan." Pediatrics International 39, no. 1 (February 1997): 105–13. http://dx.doi.org/10.1111/j.1442-200x.1997.tb03567.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Miller, JamesN. "Analysis for drugs and metabolites including anti-infective agents." Journal of Pharmaceutical and Biomedical Analysis 9, no. 5 (January 1991): 433. http://dx.doi.org/10.1016/0731-7085(91)80169-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Šíma, Martin, and Ondřej Slanař. "Dose Optimization and Targeting Strategies of Anti-Infective Agents." Pharmaceutics 15, no. 7 (July 3, 2023): 1870. http://dx.doi.org/10.3390/pharmaceutics15071870.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Setti, E. L., and R. G. Micetich. "New Trends in Antimicrobial Development." Current Medicinal Chemistry 5, no. 2 (April 1998): 101–13. http://dx.doi.org/10.2174/0929867305666220314201629.

Full text
Abstract:
The continual evolution of microbial resistance to the available classes of antibiotics poses a serious threat to the efficacy of traditional antibacterial therapy. Today, there are two main approaches that are being applied to discover better and more effective anti-infective agents against common as well as resistant pathogens: (a) the improvement of the "classical" antimicrobial agents by targeting the so called "resistance factors", and (b) the search of new anti-infective agents with novel modes of actions. This review will highlight the most relevant aspects of both of these approaches and some of the latest findings in the field of antimicrobial discovery.
APA, Harvard, Vancouver, ISO, and other styles
45

Wu, Ping-Sheng, Shu-Jung Lai, Kit-Man Fung, and Tien-Sheng Tseng. "Characterization of the structure–function relationship of a novel salt-resistant antimicrobial peptide, RR12." RSC Advances 10, no. 40 (2020): 23624–31. http://dx.doi.org/10.1039/d0ra04299d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Walder, Bernhard, Didier Pittet, and Martin R. Tramèr. "Prevention of Bloodstream Infections With Central Venous Catheters Treated With Anti-Infective Agents Depends on Catheter Type and Insertion Time: Evidence From a Meta-Analysis." Infection Control & Hospital Epidemiology 23, no. 12 (December 2002): 748–56. http://dx.doi.org/10.1086/502005.

Full text
Abstract:
Objective:To test the evidence that the risk of infection related to central venous catheters (CVCs) is decreased by anti-infective coating or cuffing.Design:Systematic review of randomized, controlled trials comparing anti-infective with inactive (control) CVCs.Interventions:Average insertion times were taken as a measurement of the length of insertion. Dichotomous data were combined using a fixed effect model and expressed as odds ratio (OR) with 95% confidence interval (CI95).Results:Two trials on antibiotic coating (343 CVCs) had an average insertion time of 6 days; the risk of BSI decreased from 5.1% with control to 0% with anti-infective catheters. There were no trials with longer average insertion times. In three trials on silver collagen cuffs (422 CVCs), the average insertion time ranged from 5 to 8.2 days (median, 7 days); the risk of BSI was 5.6% with control and 3.2% with anti-infective catheters. In another trial on silver collagen cuffs (101 CVCs), the average insertion time was 38 days; the risk of BSI was 3.7% with control and 4.3% with anti-infective catheters. In five trials on chlorhexidine-silver sulfadiazine coating (1,269 CVCs), the average insertion time ranged from 5.2 to 7.5 days (median, 6 days); the risk of BSI decreased from 4.1% with control to 1.9% with anti-infective catheters. In five additional trials on chlorhexidine–silver sulfadiazine coating (1,544 CVCs), the average insertion time ranged from 7.8 to 20 days (median, 12 days); the risk of BSI was 4.5% with control and 4.2% with anti-infective catheters.Conclusions:Antibiotic and chlorhexidine–silver sulfadiazine coatings are anti-infective for short (approximately 1 week) insertion times. For longer insertion times, there are no data on antibiotic coating, and there is evidence of lack of effect for chlorhexidine-silver sulfadiazine coating. For silver-impregnated collagen cuffs, there is evidence of lack of effect for both short- and long-term insertion.
APA, Harvard, Vancouver, ISO, and other styles
47

Hofmann, Jakob, Sabrina Klingele, Uwe Haberkorn, Gerhard Schmidmaier, and Tobias Grossner. "Impact of High-Dose Anti-Infective Agents on the Osteogenic Response of Mesenchymal Stem Cells." Antibiotics 10, no. 10 (October 16, 2021): 1257. http://dx.doi.org/10.3390/antibiotics10101257.

Full text
Abstract:
Treatment of infected nonunions and severe bone infections is a huge challenge in modern orthopedics. Their treatment routinely includes the use of anti-infective agents. Although frequently used, little is known about their impact on the osteogenesis of mesenchymal stem cells. In a high- and low-dose set-up, this study evaluates the effects of the antibiotics Gentamicin and Vancomycin as well as the antifungal agent Voriconazole on the ability of mesenchymal stem cells to differentiate into osteoblast-like cells and synthesize hydroxyapatite in a monolayer cell culture. The osteogenic activity was assessed by measuring calcium and phosphate concentrations as well as alkaline phosphatase activity and osteocalcin concentration in the cell culture medium supernatant. The amount of hydroxyapatite was measured directly by radioactive 99mTechnetium-HDP labeling. Regarding the osteogenic markers, it could be concluded that the osteogenesis was successful within the groups treated with osteogenic cell culture media. The results revealed that all anti-infective agents have a cytotoxic effect on mesenchymal stem cells, especially in higher concentrations, whereas the measured absolute amount of hydroxyapatite was independent of the anti-infective agent used. Normed to the number of cells it can therefore be concluded that the above-mentioned anti-infective agents actually have a positive effect on osteogenesis while high-dose Gentamycin, in particular, is apparently capable of boosting the deposition of minerals.
APA, Harvard, Vancouver, ISO, and other styles
48

Ang, M. Trisha C., Roger Gumbau-Brisa, David S. Allan, Robert McDonald, Michael J. Ferguson, Bruce E. Holbein, and Matthias Bierenstiel. "DIBI, a 3-hydroxypyridin-4-one chelator iron-binding polymer with enhanced antimicrobial activity." MedChemComm 9, no. 7 (2018): 1206–12. http://dx.doi.org/10.1039/c8md00192h.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Welling, Mick, Guillermina Ferro-Flores, Ioannis Pirmettis, and Carlo Brouwer. "Current Status of Imaging Infections with Radiolabeled Anti-Infective Agents." Anti-Infective Agents in Medicinal Chemistry 8, no. 3 (July 1, 2009): 272–87. http://dx.doi.org/10.2174/187152109788680180.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Boukraa, Laid. "Editorial (Thematic Issue: API-Pruducts: The Alternative Anti-Infective Agents)." Anti-Infective Agents 13, no. 1 (May 20, 2015): 2. http://dx.doi.org/10.2174/221135251301150520115554.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Anti-infective agents' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography